Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma

NCT02289898 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

207

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: Demcizumab
DRUG: Abraxane®
DRUG: gemcitabine
DRUG: Placebo

Sponsor

OncoMed Pharmaceuticals, Inc.

Collaborators

[object Object]